Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Cancer Insights

- PMLiVE

Priority review for Lilly’s ramucirumab in gastric cancer

Update comes as company posts improved revenue results

- PMLiVE

AstraZeneca moves MEK inhibitor selumetinib into phase III

Begins late-stage trials of its targeted lung cancer drug

- PMLiVE

Public unaware of main cause of liver cancer

Janssen-backed survey finds one in six people is aware of viral hepatitis role in the disease

- PMLiVE

Astellas wins NICE backing for Xtandi in prostate cancer

England’s health guidance body says drug can be used in advanced cases of the disease

- PMLiVE

Kidney cancer campaign launches in UK

The ‘Be Clear on Cancer’ campaign is aimed at raising awareness of the symptoms of bladder and kidney cancers

- PMLiVE

Merck’s vintafolide shows its worth in ovarian cancer

Phase II data shows improvement on current oncology treatments

- PMLiVE

Boehringer files nintedanib for lung cancer in Europe

Pharma company seeks approval for second oncology drug

- PMLiVE

AstraZeneca/J&J form Japanese cancer partnership

Two companies will co-promote Zytiga in prostate cancer

- PMLiVE

Lilly enters cancer collaboration in China

Signs deal with Chi-Med to develop and commercialise fruquintinib

Bayer symbol

Bayer expects five drugs to enter phase III in 2015

Hopes to follow success of recent launches

- PMLiVE

FDA gives green light to Roche for early Perjeta in breast cancer

Oncology drug can now be used before surgery in the US

- PMLiVE

UK breast cancer campaign tackles confidence failings

Breast Cancer Care aims to address negative impact on how women feel about their bodies

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links